Campaign for Action on Pharmaceutical Pollution

Sydney Jones

Press Secretary

[email protected]

Carole Mitchell

Sr. Director Communications

[email protected]

In partnership with Waxman Strategies, Mighty helped coordinate a series of letters to the Food and Drug Administration and pharmaceutical companies to encourage action on antimicrobial resistance caused by pharmaceutical pollution. Pollution of active pharmaceutical ingredients by antibiotic manufacturers creates the perfect conditions for antimicrobial resistance to develop and spread. Our letters, echoing an op-ed published in STAT, pressed for change on three fronts:

  1. U.S. drug makers should require their suppliers to stop polluting.
  2. The FDA and other relevant agencies should pressure their counterparts in India and China to toughen pollution regulations and crack down on violators.
  3. Major pharmaceutical retailers should pressure their manufacturers to ensure their supply chains are not contributing to this problem.

Pharmaceutical pollution that contributes to antimicrobial resistance is a multifaceted problem that requires action on multiple fronts to be adequately addressed. Some pharmaceutical companies have made commitments on the issue. Others, like Mylan and McKesson, have not. Read samples of the letters below.

waxman-letter-to-hhs-fda-1    others-1    13-signees

U.S. and European Carmakers Drive the Transition to Sustainable Steel, While Asian Automakers Lag Behind
A post-Chevron strategy for protecting the environment
Better protecting people and forests in the race to electrify